retatrutide weight loss results clinical trials Lilly orforglipron oral GLP-1 phase 3 trial Retatrutide NEW Phase 3 Clinical

S.ChengY.KnoxA

J nas primeiras semanas da pesquisa, os participantes tinham alcanado uma reduo de 17% do peso corporal e, com 48 semanas de tratamento, o resultado subiu para 24%

The most commonly reported adverse events were gastrointestinal in nature including nausea, vomiting, diarrhoea, and constipation a profile consistent with other incretin-based therapies

What makes Orforglipron unique among GLP-1 drugs

Tirzepatide: Shows similar trends, though long-term cardiovascular outcome data are still emerging

And while its been well-reported that GLP-1s can decrease muscle mass, that didnt explain my metrics plunge